Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T55959
(Former ID: TTDS00017)
|
|||||
Target Name |
Dopamine transporter (DAT)
|
|||||
Synonyms |
Solute carrier family 6 member 3; Sodium-dependent dopamine transporter; DAT1; DAT; DA transporter
Click to Show/Hide
|
|||||
Gene Name |
SLC6A3
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 6 Target-related Diseases | + | ||||
1 | Attention deficit hyperactivity disorder [ICD-11: 6A05] | |||||
2 | Corneal disease [ICD-11: 9A76-9A78] | |||||
3 | Narcolepsy [ICD-11: 7A20] | |||||
4 | Obesity [ICD-11: 5B80-5B81] | |||||
5 | Parkinsonism [ICD-11: 8A00] | |||||
6 | Bipolar disorder [ICD-11: 6A60] | |||||
Function |
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Click to Show/Hide
|
|||||
BioChemical Class |
Neurotransmitter:sodium symporter
|
|||||
UniProt ID | ||||||
Sequence |
MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDR
ETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELAL GQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHC NNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQL TACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSV DFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSS GFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGI DSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAA GTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSI VTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKD RELVDRGEVRQFTLRHWLKV Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T24LWC |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 7 Approved Drugs | + | ||||
1 | Altropane | Drug Info | Approved | Attention deficit hyperactivity disorder | [3] | |
2 | Cocaine | Drug Info | Approved | Anaesthesia | [4], [5], [6] | |
3 | DEXMETHYLPHENIDATE HYDROCHLORIDE | Drug Info | Approved | Attention deficit hyperactivity disorder | [6], [7] | |
4 | Ioflupane i-123 | Drug Info | Approved | Parkinson disease | [8] | |
5 | Methylphenidate | Drug Info | Approved | Attention deficit hyperactivity disorder | [9], [10] | |
6 | Modafinil | Drug Info | Approved | Narcolepsy | [6] | |
7 | Phenmetrazine | Drug Info | Approved | Obesity | [11] | |
Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
1 | Amitifadine | Drug Info | Phase 3 | Obesity | [13], [14] | |
2 | Bupropion+naltrexone | Drug Info | Phase 3 | Obesity | [15] | |
3 | NS 2359 | Drug Info | Phase 2 | Cocaine addiction | [2] | |
4 | Spiroglumide | Drug Info | Phase 2 | Stomach disease | [17] | |
5 | GSK-1360707 | Drug Info | Phase 1 | Major depressive disorder | [18] | |
6 | RTI-336 | Drug Info | Phase 1 | Cocaine addiction | [19] | |
Discontinued Drug(s) | [+] 10 Discontinued Drugs | + | ||||
1 | Amineptine | Drug Info | Withdrawn from market | Major depressive disorder | [6] | |
2 | DOV-216303 | Drug Info | Discontinued in Phase 2 | Mood disorder | [20] | |
3 | Manifaxine | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [21] | |
4 | NS-2389 | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [22] | |
5 | Radafaxine | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [23] | |
6 | SPD-473 | Drug Info | Discontinued in Phase 2 | Mood disorder | [24] | |
7 | NSD-644 | Drug Info | Discontinued in Phase 1 | Neurological disorder | [26] | |
8 | RG-7166 | Drug Info | Discontinued in Phase 1 | Major depressive disorder | [27] | |
9 | Vanoxerine | Drug Info | Discontinued in Phase 1 | Cocaine addiction | [19] | |
10 | Fluoratec | Drug Info | Terminated | Attention deficit hyperactivity disorder | [29] | |
Mode of Action | [+] 5 Modes of Action | + | ||||
Inhibitor | [+] 230 Inhibitor drugs | + | ||||
1 | Altropane | Drug Info | [30] | |||
2 | Cocaine | Drug Info | [31] | |||
3 | DEXMETHYLPHENIDATE HYDROCHLORIDE | Drug Info | [32] | |||
4 | Phenmetrazine | Drug Info | [34] | |||
5 | Amitifadine | Drug Info | [35] | |||
6 | Bupropion+naltrexone | Drug Info | [36] | |||
7 | NS 2359 | Drug Info | [20], [37] | |||
8 | Spiroglumide | Drug Info | [38] | |||
9 | GSK-1360707 | Drug Info | [39] | |||
10 | Amineptine | Drug Info | [41] | |||
11 | DOV-216303 | Drug Info | [20] | |||
12 | Radafaxine | Drug Info | [23], [44] | |||
13 | SPD-473 | Drug Info | [45] | |||
14 | RG-7166 | Drug Info | [47] | |||
15 | (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine | Drug Info | [49] | |||
16 | (+/-)-threo-3',4'-Dichloromethylphenidate amide | Drug Info | [50] | |||
17 | (+/-)-threo-3',4'-Dichlororitalinol methyl ether | Drug Info | [50] | |||
18 | (+/-)-threo-3',5'-Dichloromethylphenidate | Drug Info | [50] | |||
19 | (+/-)-threo-3',5'-Dimethylmethylphenidate | Drug Info | [50] | |||
20 | (+/-)-threo-3-Fluororitalinol | Drug Info | [50] | |||
21 | (+/-)-threo-4'-Ethylmethylphenidate | Drug Info | [50] | |||
22 | (+/-)-threo-Benzylphenidate | Drug Info | [50] | |||
23 | (+/-)-threo-Methylphenidate amide | Drug Info | [50] | |||
24 | (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate | Drug Info | [50] | |||
25 | (+/-)-threo-N-(2-Methylfuran)methylphenidate | Drug Info | [50] | |||
26 | (+/-)-threo-N-(2-Methylpyridine)methylphenidate | Drug Info | [50] | |||
27 | (+/-)-threo-N-(2-Methylthiopene)methylphenidate | Drug Info | [50] | |||
28 | (+/-)-threo-N-(2-Phenylethyl)methylphenidate | Drug Info | [50] | |||
29 | (+/-)-threo-N-(2-Phenylethyl)ritalinol | Drug Info | [50] | |||
30 | (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate | Drug Info | [50] | |||
31 | (+/-)-threo-N-(3-Methylfuran)methylphenidate | Drug Info | [50] | |||
32 | (+/-)-threo-N-(3-Methylpyridine)methylphenidate | Drug Info | [50] | |||
33 | (+/-)-threo-N-(3-Phenylpropyl)ritalinol | Drug Info | [50] | |||
34 | (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate | Drug Info | [50] | |||
35 | (+/-)-threo-N-(4-Methylpyridine)methylphenidate | Drug Info | [50] | |||
36 | (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate | Drug Info | [50] | |||
37 | (+/-)-threo-N-(4-Phenylbutyl)methylphenidate | Drug Info | [50] | |||
38 | (+/-)-threo-N-(4-Phenylbutyl)ritalinol | Drug Info | [50] | |||
39 | (+/-)-threo-N-(5-Phenylpentyl)methylphenidate | Drug Info | [50] | |||
40 | (+/-)-threo-N-(6-Phenylhexyl)methylphenidate | Drug Info | [50] | |||
41 | (+/-)-threo-N-Allylmethylphenidate | Drug Info | [50] | |||
42 | (+/-)-threo-N-Benzyl-3'-chloromethylphenidate | Drug Info | [50] | |||
43 | (+/-)-threo-N-Benzylmethylphenidate amide | Drug Info | [50] | |||
44 | (+/-)-threo-N-Methyl-30-methylmethylphenidate | Drug Info | [50] | |||
45 | (+/-)-threo-N-Propargylmethylphenidate | Drug Info | [50] | |||
46 | (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine | Drug Info | [51] | |||
47 | (2R,3R)-iodoreboxetine | Drug Info | [52] | |||
48 | (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine | Drug Info | [53] | |||
49 | (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine | Drug Info | [53] | |||
50 | (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine | Drug Info | [53] | |||
51 | (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol | Drug Info | [54] | |||
52 | (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol | Drug Info | [54] | |||
53 | (2S,3S)-iodoreboxetine | Drug Info | [52] | |||
54 | (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
55 | (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol | Drug Info | [56] | |||
56 | (R)-DULOXETINE | Drug Info | [57] | |||
57 | (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide | Drug Info | [58] | |||
58 | (R)-Norfluoxetine | Drug Info | [59] | |||
59 | (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine | Drug Info | [60] | |||
60 | (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine | Drug Info | [60] | |||
61 | (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine | Drug Info | [60] | |||
62 | (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine | Drug Info | [60] | |||
63 | (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine | Drug Info | [60] | |||
64 | (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine | Drug Info | [49] | |||
65 | (S)-Norfluoxetine | Drug Info | [59] | |||
66 | 1-(1,4-diphenylbutan-2-yl)piperazine | Drug Info | [61] | |||
67 | 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) | Drug Info | [56] | |||
68 | 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine | Drug Info | [62] | |||
69 | 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane | Drug Info | [63] | |||
70 | 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane | Drug Info | [63] | |||
71 | 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine | Drug Info | [56] | |||
72 | 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine | Drug Info | [64] | |||
73 | 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) | Drug Info | [56] | |||
74 | 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine | Drug Info | [65] | |||
75 | 1-(2-(4-fluorophenoxy)phenyl)piperazine | Drug Info | [66] | |||
76 | 1-(2-(phenoxymethyl)phenyl)piperazine | Drug Info | [66] | |||
77 | 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
78 | 1-(2-phenoxyphenyl)piperazine | Drug Info | [66] | |||
79 | 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol | Drug Info | [68] | |||
80 | 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol | Drug Info | [68] | |||
81 | 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one | Drug Info | [69] | |||
82 | 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one | Drug Info | [69] | |||
83 | 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one | Drug Info | [69] | |||
84 | 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
85 | 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
86 | 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [70] | |||
87 | 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one | Drug Info | [69] | |||
88 | 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
89 | 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
90 | 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
91 | 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [67] | |||
92 | 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
93 | 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
94 | 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
95 | 1-Benzo[b]thiophen-2-yl-cyclohexylamine | Drug Info | [63] | |||
96 | 1-Benzo[b]thiophen-2-yl-cyclopentylamine | Drug Info | [63] | |||
97 | 1-benzylpiperidine hydrochloride | Drug Info | [32] | |||
98 | 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
99 | 1-phenyl-1-(piperidin-2-yl)propan-2-one | Drug Info | [60] | |||
100 | 1-phenyl-3-aza-bicyclo[3.1.0]hexane | Drug Info | [55] | |||
101 | 10R-hydroxylobel-7-ene | Drug Info | [71] | |||
102 | 10R-hydroxylobelane | Drug Info | [71] | |||
103 | 10S-hydroxylobel-7-ene | Drug Info | [71] | |||
104 | 10S-hydroxylobelane | Drug Info | [71] | |||
105 | 1S,2R-milnacipran | Drug Info | [72] | |||
106 | 2-((2-iodophenoxy)(phenyl)methyl)morpholine | Drug Info | [73] | |||
107 | 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine | Drug Info | [73] | |||
108 | 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran | Drug Info | [74] | |||
109 | 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine | Drug Info | [64] | |||
110 | 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine | Drug Info | [75] | |||
111 | 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine | Drug Info | [75] | |||
112 | 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran | Drug Info | [74] | |||
113 | 2-(Aminomethyl)-5-phenethyltetrahydrofuran | Drug Info | [74] | |||
114 | 2-(N,N-Diethylamino)-3'-chloropropiophenone | Drug Info | [76] | |||
115 | 2-(N-Cyclopentylamino)-3'-bromopropiophenone | Drug Info | [69] | |||
116 | 2-(N-Cyclopentylamino)-3'-chloropropiophenone | Drug Info | [76] | |||
117 | 2-(N-Cyclopentylamino)-3'-fluoropropiophenone | Drug Info | [69] | |||
118 | 2-(N-Cyclopentylamino)-3'-methylpropiophenone | Drug Info | [69] | |||
119 | 2-(N-Cyclopropylamino)-3-chloropropiophenone | Drug Info | [76] | |||
120 | 2-(N-Isopropylamino)-3'-chloropropiophenone | Drug Info | [76] | |||
121 | 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone | Drug Info | [69] | |||
122 | 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone | Drug Info | [69] | |||
123 | 2-(N-Pyrrolidinyl)-3'-methylpropiophenone | Drug Info | [69] | |||
124 | 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone | Drug Info | [76] | |||
125 | 2-(N-tert-Butylamino)-3'-chloroheptanophenone | Drug Info | [76] | |||
126 | 2-(N-tert-Butylamino)-3'-chlorooctanophenone | Drug Info | [76] | |||
127 | 2-(N-tert-Butylamino)-4'-chloropropiophenone | Drug Info | [76] | |||
128 | 2-(N-tert-Butylamino)propiophenone | Drug Info | [76] | |||
129 | 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one | Drug Info | [69] | |||
130 | 2-(tert-butylamino)-1-p-tolylpropan-1-one | Drug Info | [69] | |||
131 | 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone | Drug Info | [76] | |||
132 | 2-(tert-Butylamino)-3',4'-dichloropentanophenone | Drug Info | [76] | |||
133 | 2-(tert-Butylamino)-3',5'-difluoropropiophenone | Drug Info | [76] | |||
134 | 2-(tert-Butylamino)-3'-fluoropropiophenone | Drug Info | [76] | |||
135 | 2-Amino-1-(4-methylthiophenyl)propane | Drug Info | [77] | |||
136 | 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran | Drug Info | [74] | |||
137 | 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran | Drug Info | [74] | |||
138 | 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran | Drug Info | [74] | |||
139 | 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran | Drug Info | [74] | |||
140 | 2-Aminomethyl-5-(phenyl)tetrahydrofuran | Drug Info | [74] | |||
141 | 2-phenoxy-3-(piperidin-4-yl)pyridine | Drug Info | [75] | |||
142 | 2-phenylpiperidine hydrochloride | Drug Info | [32] | |||
143 | 2pyrrolidin-1-yl-1-phenylpentan-1-one | Drug Info | [67] | |||
144 | 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol | Drug Info | [65] | |||
145 | 3-(3,4-dichlorophenyl)-2-nortropene | Drug Info | [78] | |||
146 | 3-(4-Trifluoromethylphenyl)-2-nortropene | Drug Info | [78] | |||
147 | 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane | Drug Info | [78] | |||
148 | 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane | Drug Info | [79] | |||
149 | 3-Phenyl-2-nortropene | Drug Info | [78] | |||
150 | 3alpha-(bis-chloro-phenylmethoxy)tropane | Drug Info | [80] | |||
151 | 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine | Drug Info | [81] | |||
152 | 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine | Drug Info | [66] | |||
153 | 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine | Drug Info | [66] | |||
154 | 4-(2-(2-fluorobenzyloxy)phenyl)piperidine | Drug Info | [66] | |||
155 | 4-(2-(3-chlorophenoxy)phenyl)piperidine | Drug Info | [66] | |||
156 | 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine | Drug Info | [66] | |||
157 | 4-(2-(3-fluorophenoxy)phenyl)piperidine | Drug Info | [66] | |||
158 | 4-(2-(4-fluorobenzyloxy)phenyl)piperidine | Drug Info | [66] | |||
159 | 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine | Drug Info | [66] | |||
160 | 4-(2-(4-fluorophenoxy)phenyl)piperidine | Drug Info | [66] | |||
161 | 4-(2-(benzyloxy)-3-fluorophenyl)piperidine | Drug Info | [66] | |||
162 | 4-(2-(benzyloxy)-6-fluorophenyl)piperidine | Drug Info | [66] | |||
163 | 4-(2-(benzyloxy)phenyl)piperidine | Drug Info | [66] | |||
164 | 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine | Drug Info | [66] | |||
165 | 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine | Drug Info | [66] | |||
166 | 4-(2-fluoro-6-phenoxyphenyl)piperidine | Drug Info | [66] | |||
167 | 4-(2-phenoxyphenyl)piperidine | Drug Info | [66] | |||
168 | 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile | Drug Info | [67] | |||
169 | 4-(3-fluoro-2-phenoxyphenyl)piperidine | Drug Info | [66] | |||
170 | 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | [82] | |||
171 | 4-[(diphenylmethyl)amino]-2-phenylquinazoline | Drug Info | [51] | |||
172 | 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline | Drug Info | [55] | |||
173 | 6-(piperidin-4-ylmethoxy)-2-naphthonitrile | Drug Info | [49] | |||
174 | 7-(piperidin-4-ylmethoxy)-2-naphthonitrile | Drug Info | [49] | |||
175 | 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane | Drug Info | [79] | |||
176 | 8R-hydroxylobel-9-ene | Drug Info | [83] | |||
177 | 8S-hydroxylobelane | Drug Info | [71] | |||
178 | AMINOBENZTROPINE | Drug Info | [84] | |||
179 | ANOLOBINE | Drug Info | [85] | |||
180 | ANONAINE | Drug Info | [85] | |||
181 | ANTIOQUINE | Drug Info | [85] | |||
182 | Benzyl-(2-phenyl-quinazolin-4-yl)-amine | Drug Info | [51] | |||
183 | Bip-tyr(3bzl)-thr-pro-lys-thr | Drug Info | [87] | |||
184 | Bip-tyr-thr-ala-pro-phe | Drug Info | [87] | |||
185 | Bip-tyr-thr-pro-lys-thr | Drug Info | [87] | |||
186 | Bip-tyr-thr-pro-thr(obzl)-gly | Drug Info | [87] | |||
187 | Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine | Drug Info | [88] | |||
188 | Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine | Drug Info | [89] | |||
189 | COCAINE.HCL | Drug Info | [32] | |||
190 | COCLAURINE | Drug Info | [85] | |||
191 | D-211A | Drug Info | [90] | |||
192 | D-211B | Drug Info | [90] | |||
193 | D-254C | Drug Info | [90] | |||
194 | D-257A | Drug Info | [90] | |||
195 | D-257C | Drug Info | [90] | |||
196 | DIMETHYLGRISABINE | Drug Info | [85] | |||
197 | Erythro-3,4-dichloromethylphenidate hydrochloride | Drug Info | [32] | |||
198 | GB-12819 | Drug Info | [91] | |||
199 | HOMOAROMOLINE | Drug Info | [85] | |||
200 | Indatraline | Drug Info | [92] | |||
201 | ISOPILINE | Drug Info | [85] | |||
202 | ISOTETRANDRINE | Drug Info | [85] | |||
203 | Methyl 2-(naphthalen-2-yl)benzoate | Drug Info | [93] | |||
204 | METHYLENEDIOXYAMPHETAMINE | Drug Info | [94] | |||
205 | METHYLENEDIOXYMETHAMPHETAMINE | Drug Info | [77], [95] | |||
206 | N,Ndimethyl milnacipran | Drug Info | [97] | |||
207 | N-Benzylmethylphenidate | Drug Info | [50] | |||
208 | NISOXETINE | Drug Info | [89] | |||
209 | NORBOLDINE | Drug Info | [85] | |||
210 | NORSTEPHALAGINE | Drug Info | [85] | |||
211 | O-2442 | Drug Info | [35] | |||
212 | OBABERINE | Drug Info | [85] | |||
213 | Para-chloroamphetamine | Drug Info | [77] | |||
214 | PF-18298 | Drug Info | [56] | |||
215 | PF-3409409 | Drug Info | [98] | |||
216 | PMID25037917C58 | Drug Info | [99] | |||
217 | PSEUDOCOCAINE | Drug Info | [100] | |||
218 | PYROVALERONE | Drug Info | [70] | |||
219 | R-226161 | Drug Info | [101] | |||
220 | Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride | Drug Info | [32] | |||
221 | Threo-3,4-dichlororitalinol hydrochloride | Drug Info | [32] | |||
222 | Threo-N-ethylritalinol hydrochloride | Drug Info | [32] | |||
223 | Threo-ritalinol hydrochloride | Drug Info | [32] | |||
224 | Threo-ritalinol methyl ether hydrochloride | Drug Info | [32] | |||
225 | WIN-35065 | Drug Info | [102] | |||
226 | WIN-35066-2 | Drug Info | [103] | |||
227 | [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine | Drug Info | [68] | |||
228 | [3H]GBR12935 | Drug Info | [104] | |||
229 | [3H]WIN35428 | Drug Info | [104], [105] | |||
230 | [N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX) | Drug Info | [106] | |||
Modulator | [+] 7 Modulator drugs | + | ||||
1 | Ioflupane i-123 | Drug Info | [6] | |||
2 | Modafinil | Drug Info | [33] | |||
3 | RTI-336 | Drug Info | [40] | |||
4 | Manifaxine | Drug Info | [42] | |||
5 | NS-2389 | Drug Info | [43] | |||
6 | Fluoratec | Drug Info | [48] | |||
7 | MMDA | Drug Info | [96] | |||
Blocker | [+] 2 Blocker drugs | + | ||||
1 | Methylphenidate | Drug Info | [1] | |||
2 | Vanoxerine | Drug Info | [19] | |||
Activator | [+] 1 Activator drugs | + | ||||
1 | NSD-644 | Drug Info | [46] | |||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | Beta-methoxyamphetamine | Drug Info | [86] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Synaptic vesicle cycle | hsa04721 | Affiliated Target |
![]() |
Class: Organismal Systems => Nervous system | Pathway Hierarchy | ||
Dopaminergic synapse | hsa04728 | Affiliated Target |
![]() |
Class: Organismal Systems => Nervous system | Pathway Hierarchy |
Degree | 5 | Degree centrality | 5.37E-04 | Betweenness centrality | 1.40E-04 |
---|---|---|---|---|---|
Closeness centrality | 2.03E-01 | Radiality | 1.35E+01 | Clustering coefficient | 1.00E-01 |
Neighborhood connectivity | 1.86E+01 | Topological coefficient | 2.07E-01 | Eccentricity | 13 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 5 KEGG Pathways | + | ||||
1 | Dopaminergic synapse | |||||
2 | Parkinson's disease | |||||
3 | Cocaine addiction | |||||
4 | Amphetamine addiction | |||||
5 | Alcoholism | |||||
Panther Pathway | [+] 3 Panther Pathways | + | ||||
1 | Adrenaline and noradrenaline biosynthesis | |||||
2 | Parkinson disease | |||||
3 | Dopamine receptor mediated signaling pathway | |||||
PID Pathway | [+] 1 PID Pathways | + | ||||
1 | Alpha-synuclein signaling | |||||
Reactome | [+] 1 Reactome Pathways | + | ||||
1 | Na+/Cl- dependent neurotransmitter transporters | |||||
WikiPathways | [+] 6 WikiPathways | + | ||||
1 | Monoamine Transport | |||||
2 | NRF2 pathway | |||||
3 | Dopaminergic Neurogenesis | |||||
4 | Parkinsons Disease Pathway | |||||
5 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
6 | Neurotransmitter Clearance In The Synaptic Cleft |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5. | |||||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 3 | ClinicalTrials.gov (NCT00596908) 123I-ALTROPANE Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor. U.S. National Institutes of Health. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2286). | |||||
REF 5 | Drug information of Cocaine, 2008. eduDrugs. | |||||
REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 7 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033419) | |||||
REF 8 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||||
REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7236). | |||||
REF 10 | Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53. | |||||
REF 11 | Drug information of Phenmetrazine, 2008. eduDrugs. | |||||
REF 12 | ClinicalTrials.gov (NCT01950455) Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes. U.S. National Institutes of Health. | |||||
REF 13 | DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol. 2004 Dec;44(12):1360-7. | |||||
REF 14 | Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 Summer;12(2):123-34. | |||||
REF 15 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43. | |||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037483) | |||||
REF 17 | Progress medicinal chem PMC37H. Page(48). | |||||
REF 18 | ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health. | |||||
REF 19 | Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. | |||||
REF 20 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. | |||||
REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006906) | |||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009012) | |||||
REF 23 | Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. | |||||
REF 24 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010517) | |||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030892) | |||||
REF 26 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571) | |||||
REF 27 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) | |||||
REF 28 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011877) | |||||
REF 29 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016245) | |||||
REF 30 | Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. | |||||
REF 31 | Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. | |||||
REF 32 | Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. | |||||
REF 33 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 34 | Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. | |||||
REF 35 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927). | |||||
REF 36 | Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. | |||||
REF 37 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | |||||
REF 38 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||||
REF 39 | Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. | |||||
REF 40 | Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.AAPS J.2006 Mar 24;8(1):E196-203. | |||||
REF 41 | Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai. 1997 Sep;80(9):587-92. | |||||
REF 42 | Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9. | |||||
REF 43 | Clinical pipeline report, company report or official report of Neurosearch. | |||||
REF 44 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||||
REF 45 | Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. | |||||
REF 46 | NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. | |||||
REF 47 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) | |||||
REF 48 | Technepine: a high-affinity 99m-technetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse. 1996 Mar;22(3):239-46. | |||||
REF 49 | Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. | |||||
REF 50 | Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. | |||||
REF 51 | Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. | |||||
REF 52 | New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. | |||||
REF 53 | Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. | |||||
REF 54 | Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. | |||||
REF 55 | Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. | |||||
REF 56 | Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. | |||||
REF 57 | 1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. | |||||
REF 58 | Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. | |||||
REF 59 | Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. | |||||
REF 60 | Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. | |||||
REF 61 | Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. | |||||
REF 62 | Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. | |||||
REF 63 | Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. | |||||
REF 64 | Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. | |||||
REF 65 | N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. | |||||
REF 66 | Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. | |||||
REF 67 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. | |||||
REF 68 | Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. | |||||
REF 69 | Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. | |||||
REF 70 | A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem. 2009 Jun 1;17(11):3770-4. | |||||
REF 71 | Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. | |||||
REF 72 | Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72. | |||||
REF 73 | Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. | |||||
REF 74 | 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. | |||||
REF 75 | Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. | |||||
REF 76 | Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. | |||||
REF 77 | Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. | |||||
REF 78 | Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. | |||||
REF 79 | 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. | |||||
REF 80 | Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. | |||||
REF 81 | Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. | |||||
REF 82 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | |||||
REF 83 | Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15;18(2):640-9. | |||||
REF 84 | 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7. | |||||
REF 85 | Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. | |||||
REF 86 | Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. | |||||
REF 87 | Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. | |||||
REF 88 | Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. | |||||
REF 89 | Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. | |||||
REF 90 | Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. | |||||
REF 91 | Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2387-90. | |||||
REF 92 | Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17. | |||||
REF 93 | Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74. | |||||
REF 94 | Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. | |||||
REF 95 | The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. | |||||
REF 96 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 97 | Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. | |||||
REF 98 | Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. | |||||
REF 99 | Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90. | |||||
REF 100 | Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1831-6. | |||||
REF 101 | Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. | |||||
REF 102 | Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. | |||||
REF 103 | Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9. | |||||
REF 104 | Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35. | |||||
REF 105 | 3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41. | |||||
REF 106 | A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem. 1997 Jun 6;40(12):1835-44. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.